Brain Cancer Vaccine Clinical Trial Begins
Posted on: Thursday, 7 February 2008, 21:00 CST
Two U.S. doctors are seeking candidates for their phase II clinical trial of a personalized brain cancer vaccine.
Dr. Patrick Kelly and Dr. Michael Gruber of New York University Medical Center says it is anticipated that the vaccine can increase survival rates by 50 percent.
When the initial study of this vaccine was conducted at the University of California, Los Angeles, two-thirds of the patients were still alive after two years, compared to one-third who only received standard treatment. In two-fifths of the vaccine-treated patients, who survived two years there has been no evidence of the disease, the study said.
The vaccine is made by taking a portion of a patient's brain tumor and combining it with dendritic white blood cells. Once the vaccine is injected beneath the skin of the patient it should create an immune reaction resulting in killing the cancer cells.
Patients who are candidates for this phase II trial must be newly-diagnosed, and have not had any other treatment, including chemotherapy and/or radiation. They will first undergo a minimally-invasive procedure to remove the tumor, Kelly said.
Source: United Press International
Related Articles
- Multi-Pronged Therapeutic Cancer Vaccine Regimen to Be Studied in Melanoma Patients
- Hepatitis C Virus DNA Vaccine Shows Safety When Delivered By Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
- American Heart Association/American College of Cardiology Scientific Advisory: Annual Flu Shot May Protect Cardiovascular Disease Patients
- CDC Links 3 More Reactions to Vaccine, WSJ
- Familymeds Holds Flu Clinics in Pharmacy Locations
- Hepatitis A Vaccine not Widely Used for Hepatitis C Patients
- Updated Survival Results From BLP25 Liposome Vaccine (L-BLP25) Phase IIb Study From Patients With Stage IIIB Non-Small Cell Lung Cancer (NSCLC) Presented
- AustCancer Completes Patient Recruitment for Phase IIb Pentrys Trial
- Vaccine for Chronic Myeloid Leukemia Highlighted in Lancet Publication; Vaccine Significantly Improves Molecular Remission Rate of Patients With Persistent CML
- Reduced Hospitalizations and Death Associated With Influenza Vaccination Among Patients With and Without Diabetes
 |
 |
User Comments (0)
RSS Feeds